In October 2026, commodities led market gains with a 4.08% increase, pushing their year-to-date return to 60.55%. U.S. real estate, bonds, and cash also posted positive returns, while equities and hedge funds experienced declines. Hedge funds fell 1.55% in October, ending with a 5.88% gain for the year, and managed futures dropped 1.24%, breaking their streak of positive returns. This mixed performance highlights the varied market conditions investors faced during the month.
The October 2026 asset class scoreboard shows commodities leading with a 4.08% gain and a year-to-date return of 60.55%. For readers following this market context, Pluang's snapshot as of Nov 06, 2026 03:01 WIB reports a breadth of 16 rising and 134 falling US stocks among 150 priced. Notable movers include AMAT down 10.97%, TSLA down 10.77%, and HOOD down 10.00%, with typical hold times ranging from 68 to 89 days and Pluang order activity slightly favoring buys.
CRCAM Toulouse 31 announced the publication and filing of its financial information report for the quarter ending September 30, 2026. The report is accessible to the public on the company's website under the regulatory information section for 2026. T...
Scout Clean Energy has announced that its 183 MW Nimbus Wind Farm in Carroll County, Arkansas, is now commercially operational after two years of construction. The wind farm, the largest in Arkansas, generates enough electricity to power over 40,000 ...
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Following Binance's $6.3 billion hack, the Federal Reserve and the Office of the Comptroller of the Currency (OCC) have contacted U.S. banks to inquire about any unusual activity, service disruptions, or system vulnerabilities. This oversight aims to...
Windward Bio Group AG plans to raise over $100 million through a U.S. IPO to support the development of its clinical-stage asthma drug, WIN378, which has shown promising Phase 2/3 results. The company expects pivotal trial data by mid-2027 and target...
